Mauro Vitali, head of Oncology Business Division of Daiichi Sankyo Italia Photos: Courtesy of Daiichi Sankyo

As one of the leading Japanese pharmaceutical companies with headquarters in Europe, Daiichi Sankyo aims to revolutionize treatment standards.

Daiichi Sankyo, a pharmaceutical group boasting over a century of scientific expertise, is committed to improving the lives of cancer patients. 

Its aim is to make a real impact by revolutionizing current treatment standards through the introduction of innovative and increasingly effective therapies. 

How? The consensus among oncologists worldwide is clear: the future of treatments is shifting toward targeted therapy. 

This approach, already successfully underway, differs from traditional approaches in that it targets tumors precisely while causing minimal harm to healthy cells in the body. 

And this is what Daiichi Sankyo researchers have finally accomplished after years of research and experimentation, with encouraging results from this technology thus far. 

While initially proven effective in treating breast cancer, promising results are now being achieved for other cancer types. 

Meanwhile, research continues tirelessly, with the aim of further refining techniques and broadening accessibility to patients worldwide. 

Such progress is fueled by substantial investments in research and development, which account for approximately 24 percent of the Japanese company's annual revenue. 

Operating in over 25 countries, Daiichi Sankyo is now one of Japan's largest pharmaceutical companies, with headquarters in Europe. 

It is renowned worldwide for its pioneering scientific research, dating back to milestones like the first crystallization of adrenaline and the discovery of vitamin B1 in the early 1900s. 

Adaptive technology

With its European headquarters situated in Munich, overseeing a network of 13 branches, the Tokyo-based company has a precise and ambitious goal: to make tangible improvements in the lives of cancer patients, rewriting current treatment standards through the introduction of innovative and increasingly effective therapies.

The technologies designed and developed in research laboratories in Japan are bringing new hope to thousands of patients. 

These innovations, applied to science and pharmacology and integrated with advancements in molecular biology, are assisting the Japanese company in achieving the goal of developing extremely precise and adaptable therapies. These therapies aim to safeguard the patient's health and quality of life as much as possible.

 

Investing in R&D

Daiichi Sankyo is solidifying its position as a leader in oncology by making substantial investments in research and development, allocating over 24 percent of its annual revenue. 

This commitment is already yielding tangible results, improving treatment outcomes for patients with various types of cancer. In just a decade, this approach has transformed Daiichi Sankyo into a leading company in the oncology sector. 

The company emphasizes the importance of listening to patients and healthcare professionals for the development of clinical trial protocols and advocates for public awareness about prevention and early diagnosis. These efforts are critical for the development of effective and safe treatments.

Daiichi Sankyo, European headquarters in Munich

Production capacity

Each year, the facility located in the state of Bavaria, Germany, produces over 90 million packages and approximately 2 billion tablets, which are then distributed to more than 50 countries worldwide. 

The production facility at Pfaffenhofen comprises a dedicated section for the manufacturing of biotechnological products, alongside distinct departments for the production of semi-solid and liquid pharmaceuticals (such as ointments, gels, and liquids) and solid pharmaceuticals (including tablets and coated tablets). 

Additionally, at the Altkirch facility in France, Daiichi Sankyo manufactures the active substances used in its traditional pharmaceutical products under the Luitpold brand, which is also owned by the company.

Daiichi Sankyo remains committed to the Japanese philosophy of continuous improvement, striving to enhance the quality of life for patients worldwide with perseverance and determination. 

Constant innovation

With this ambitious goal in mind, the company's research laboratories continue to operate tirelessly. 

Daiichi Sankyo fosters an environment of constant innovation, where a continuous flow of ideas and insights fuels the development of increasingly advanced research while always prioritizing patient needs. 

As a result, the company collaborates synergistically with scientific societies, patient associations, the medical community, stakeholders, and all those capable of significantly contributing to the pursuit of effective solutions for improving the quality of life for oncology patients. 

This collaborative effort aims to revolutionize current treatment standards, giving patients hope for the future.